FDA, EMA Back Safety Of Diabetes Drugs Targeted In MDL

Law360, New York (February 27, 2014, 5:56 PM EST) -- The U.S. Food and Drug Administration and European Medicines Agency found no firm evidence Thursday that diabetes drugs made by Merck & Co. Inc., Novo Nordisk Inc. and others cause pancreatic cancer, as plaintiffs allege in multidistrict litigation against the drugmakers in California.

A class of Type 2 diabetes drugs known as incretin mimetics has been under regulatory scrutiny since academic researchers suggested in early 2013 that they may lead to an increased risk of pancreatitis and precancerous changes in the pancreas. The manufacturers of the drugs...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.